Publications
-
2022-03-25Targeting CD47 for cancer immunotherapyZhongxing Jiang, Hao Sun, Jifeng Yu, Wenzhi Tian, Yongping Song. (2021). Targeting CD47 for cancer immunotherapy. Journal of Hematology & Oncology. 14, 180-198. Read the link: https://jhoonline.biomedcentral.com/articles/10.1186/s13......2022-03-25see more -
2022-03-25How to select IgG subclasses in developing anti-tumor therapeutic antibodiesJifeng Yu, Yongping Song , and Wenzhi Tian. (2020). How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology & Oncology. 2020, 13, 45-54. Read the link: https://jhoonline.biomedcentral.com/......2022-03-25see more -
2022-03-25Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancerZhang X, Wang Y, Fan J, Chen W, Luan J, Mei X, Wang S, Li Y, Ye L, Li S, Tian W, Yin K, Ju D. (2019). Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. J Immunother Cancer. 7 (1):346. ......2022-03-25see more -
2022-03-25Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastomaZhang X, Wang S, Nan Y, Fan J, Chen W, Luan J, Wang Y, Liang Y, Li S, Tian W, Ju D. (2018). Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. Appl Microbiol Biotechnol. 102(15):6503-6513. ......2022-03-25see more -
2022-03-25Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastomaZhang X, Chen W ,Fan J, Wang S, Xian Z, Luan J, Li Y, Wang Y, Nan Y, Luo M, Li S, Tian W, Ju D. (2018). Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma. Carcinogenesis. 39(5):689-699. Read ......2022-03-25see more